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Spinal muscular atrophy (SMA) is a childhood disorder caused by loss of the SMN gene. Pathological hall-
marks are spinal cord motor neuron death, neuromuscular junction dysfunction and muscle atrophy. The
first SMN genetic therapy was recently approved and other SMN-dependent treatments are not far be-
hind. However, not all SMA patients will reap their maximal benefit due to limited accessibility, high costs
and differential effects depending on timing of administration and disease severity. The repurposing of
commercially available drugs is an interesting strategy to ensure more rapid and less expensive access to
new treatments. In this mini-review, we will discuss the potential and relevance of repositioning drugs
currently used for neurodegenerative, neuromuscular and muscle disorders for SMA.
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Spinal muscular atrophy (SMA) is an inherited neuromuscular disorder characterized by motor neuron loss and
muscle atrophy. SMA is the leading genetic cause of infant mortality [1,2]. Approximately 96% of SMA cases have
been mapped to deletions and loss-of-function mutations within the ubiquitously expressed SMN1 gene, which
holds several housekeeping functions, including RNA metabolism, small nuclear ribonucleoprotein assembly and
spliceosomal regulation as well as numerous cell-specific roles [3,4]. In addition, SMN1 has an inverted duplicate
gene called SMN2, which carries out similar functions, although this is limited by an 840C>T polymorphism that
causes 90% of expressed proteins to be truncated and non-functional via exon 7 exclusion [5]. While compensated
by the fully expressed SMN1 in healthy individuals, SMN2 is clinically relevant in SMA as a disease modifier due
to an association of increased copy number with reduced severity [5,6].
Presently, the only clinically approved treatment for SMA is nusinersen (Spinraza™), an antisense oligonucleotide
that targets SMN2 to promote the production of higher levels of functional SMN protein through exon 7
inclusion [7,8]. However, as nusinersen is a relatively new therapy, there are no longitudinal studies to assess its
long-term effects, although reports suggest its success is dependent upon the treatment being administered as early as
possible [9–11]. These limitations, along with others, highlight a host of issues such as limited treatment viability for
type 2 and 3 patients, whose symptoms are milder and develop in later years, and elevated costs associated with both
newborn screening and treatment (estimated at £450,000 for the first year and £225,000 for subsequent years) [11–
13]. As such, National Health Service England and Wales, for example, have only recently approved funding of
nusinersen (May 2019), leaving several patients without access to any clinical treatments during a crucial period [13].
While a cohort of additional novel drugs designed to enhance SMN expression are in development, none have yet
passed the Phase III clinical trial stages (Table 1) and similar high costs have been predicted (∼US$2 million per
treatment) [14,15]. Therefore, more cost-efficient drugs are required to ensure accessibility of treatments for all SMA
patients.
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Table 1. Status of SMN-dependent drugs in clinical trials for spinal muscular atrophy.
ClinicalTrials.gov ID Therapeutic Activity Current status (as of May 2019)
NCT02268552 Branaplam™ Oral small-molecule stabilizer of U1-snRNP complex and SMN2
pre-mRNA to promote higher expression of full-length SMN2
mRNA
Phase II trials
NCT03779334 Risdiplam™ Oral small-molecule promoter of full length SMN2 mRNA via
splicing modification
Phase II trials
NCT02122952 Zolgensma™ Gene therapy delivery of exogenous SMN1 via adeno-associated
virus effector to promote higher SMN abundance
Phase I trials
NCT02240355 R06885247 Oral small-molecule splicing modulator of SMN2 pre-mRNA to
promote higher expression of full length SMN2 mRNA
Terminated
Typically, clinical drug development is a very long overhaul with some drugs taking up to 20 years before being
approved [16]. Due to the limited availability of treatments for SMA and the urgency in getting them to patients,
a valid alternative is the repositioning (or repurposing) of drugs originally designed to treat other conditions [17].
Compared with novel drugs, most repositioned drugs have passed safety efficacy tests for human administration,
thus allowing a complete omission of Phase I trials [17]. Furthermore, information such as efficacy dosage, side effects
and formulation costs are already known, making trials of repositioned drugs more cost and time effective [17].
Drug repositioning is not a new concept in the fields of non-neurodegenerative diseases and has opened several
novel avenues of research [17–19]. Indeed, the Type 2 diabetes drug metformin is now being evaluated in clinical
trials for breast and endometrial-based cancers, while the controversial morning sickness drug thalidomide is a
possible candidate for Alzheimer’s disease (AD) [20–26]. However, very little research on drug repositioning has
been conducted in the context of inherited neurodegenerative diseases. This review will discuss how commercial
drugs originally designed for other neurodegenerative, neuromuscular and muscular disorders have the potential
to be repositioned to treat the central nervous system (CNS), neuromuscular junction (NMJ) and skeletal muscle
pathologies observed in SMA.
Repositioning drugs to target CNS pathologies in SMA
The loss of motor neurons in the anterior horn of the spinal cord is the canonical feature of SMA [27]. While the
genetic basis behind SMA is now well understood, it has not yet been elucidated how and why loss of SMN affects
and causes motor neuron degeneration [27]. Besides its ubiquitous localization within nuclear Gemini of coiled
bodies (Gems), SMN is also specifically abundant in the axon and synaptic regions of motor neurons where it
regulates mRNA transport, actin dynamics and vesicle release [28–31]. This is supported by studies showing neurite
outgrowth, differentiation and synaptic defects in SMN-depleted neuronal cells, suggesting that CNS-specific
functions of SMN are dysregulated in SMA [31–33]. Commercial drugs that modulate similar regulatory pathways
in the CNS might therefore be beneficial in SMA patients.
One plausible repositioning strategymay be through identifying drugs that are currently used to treat other motor
neuron diseases such as amyotrophic lateral sclerosis (ALS). Indeed, the ALS drug riluzole (Rilutek™ or Teglutik™),
a pharmacological compound thought to promote neuroprotection through Ca2+-activated K+ channel-mediated
glutamate reduction, has already been evaluated in clinical trials for SMA, albeit with limited success in improving
survival rates (ClinicalTrials.Gov ID: NCT00774423) [34–38].
While the repositioning of riluzole for SMA is ongoing, other ALS drugs have not yet made that leap, including
rasalgiline (Azilect™), an irreversible MOA-B inhibitor (Figure 1) [39]. TheMOA-B isoform is expressed in the outer
membrane of mitochondria with a neuron-specific role in oxidative deamination of monoamine neurotransmit-
ters [40–43]. Based upon evidence of MOA-B upregulation in rodent models of Parkinson’s disease (PD), rasalgiline
was initially evaluated in clinical trials for PD (ClinicalTrials.Gov ID: NCT00203138) and received EMA and US
FDA approval in 2005 and 2006, respectively [43].
Recently, rasalgiline underwent Phase II clinical trials in ALS patients, either alone or in combination with
riluzole, with the latter demonstrating moderate success, which is thought to be due to rasalgiline’s neuropro-
tective role through promoting mitochondrial stability (ClinicalTrials.Gov ID: NCT01786603; NCT01879241;
NCT01232738) [44–46]. Indeed, increased MOA-B activity could contribute to mitochondrial dysfunction and
neurodegeneration via accumulation of its aldehyde and reactive oxygen species by-products [47–50]. Given that mi-
tochondrial instability has been reported in pre-symptomatic SMA motor neurons, rasalgiline could be a treatment
option to improve mitochondrial stability and delay motor neuron degeneration (Figure 1) [51].
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Figure 1. Targets for survival motor neuron-independent drug repositioning strategies for spinal muscular atrophy.
Overview of pathological molecular effectors or biological pathways (in red) that could be therapeutically modulated
by commercially available drugs (in blue) to treat CNS, NMJ and skeletal muscle pathologies in spinal muscular
atrophy.
NMJ: Neuromuscular junction.
Modulating the aberrant inflammation of nervous tissue (neuroinflammation) can also help minimize motor
neuron death. The pathological impacts of neuroinflammation, predominantly mediated by astrocytes and mi-
croglia, have been associated with several neurodegenerative diseases such as AD [52]. Microglia are specialized
macrophage cells that regulate the removal of damaged neurons, plaques and infectious agents [53]. However, the
chronic release of pro-inflammatory factors by M1 microglia can result in neuroinflammation-induced neuronal
loss [54–57]. Studies in rodents identified the colony-stimulating factor 1 receptor, a member of the RTK family,
as a key promoter of microglia proliferation and viability [58–61]. The RTK inhibitor masitinib (Masivet™) has
been demonstrated to reduce the levels of microglia via colony-stimulating factor 1 receptor inhibition (Figure 1),
thus decreasing neuronal degeneration in clinical trials for AD (ClinicalTrials.Gov ID: NCT01872598) [62–64].
Masitinib has recently been evaluated in SOD1G93A ALS rats, where administration of the drug delayed disease
progression as well as reduced both microglial activity and neuroinflammation [65]. Furthermore, emerging results
from Phase III clinical trials of masitinib in ALS patients are promising, with reports of delayed neuronal de-
generation, although the extent of the delay remains unclear (ClinicalTrials.Gov ID: NCT02588677) [66]. Recent
reports also support a role for neuroinflammation in SMA pathogenesis [67]. Indeed, increased microgliosis and
release of the pro-inflammatory IL-6 cytokine by microglia have been described in SMA mice [33,68]. In addition,
astrocytosis was observed in the spinal cord of SMA mice at early symptomatic stages, when motor neuron loss is
first detected [69,70]. The role of astrocytes in SMA pathology was further supported by experiments demonstrating
that astrocyte-specific restoration of SMN expression in SMA improves disease phenotypes [70]. Recent work has
also identified the Notch pathway as a mediator of neuroinflammatory activity in SMA mice [71]. Thus, drugs that
reduce neuroinflammation such as masitinib may provide significant therapeutic benefits for SMA (Figure 1).
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Figure 2. Proposed experimental model for drug repositioning strategies. Proteomic and transcriptomic approaches can be used to
define the differential expression patterns of genes, proteins and biological pathways between diseased and healthy states. Published
literature or integrated publicly available drug databases allow for the uncovering of commercially available drugs that can restore the
aberrant molecular profiles in the diseased state. The drugs then require to first be validated for safety and efficacy in relevant in vitro
and in vivo models. Successful drug candidates can then be evaluated in clinical trials, with Phase I usually bypassed as information
regarding safety and dosages are known. Finally, the drug is approved for patient use if it demonstrates benefits in clinical trials.
Preventing and/or delaying motor neuron death in SMA is a therapeutic priority and repositioning neuropro-
tective drugs such as rasalgiline and masitinib for SMA has the potential to rapidly expand the number of available
CNS-specific treatments.
Repositioning drugs to target NMJ pathologies in SMA
SMA pathology also affects the NMJ, a specialized synaptic region between the motor nerve terminal and skeletal
muscle fiber that contributes to contraction via an ACh and nicotinic AChR interaction [72]. In both severe and
intermediate SMA mice, NMJ defects include neurofilament accumulation, axonal sprouting, immature motor
endplate development, impaired synaptic regions and dysregulated AChR clustering, the latter being a crucial step
in NMJ development [72,73]. Thus, drugs currently aimed at modulating NMJ activity (pre- and post-synaptic) are
an interesting avenue for SMA.
Lambert-Eaton myasthenic syndrome is an autoimmune disorder caused by antibodies that target motor neuron
voltage-gated Ca2+ channels, resulting in a pre-synaptic NMJ pathology [74]. Amifampridine (Firdapse™) has been
used to treat this disorder by blocking pre-synaptic K+ channels to allow an increased duration of ACh release
(Figure 1) [75,76]. Interestingly, impairments in neuronal excitation of SMN-deficient motor neurons were similarly
caused by defective voltage-gated Ca2+ channels, suggesting that amifampridine could provide therapeutic benefits
in SMA (Figure 1) [77]. Furthermore, with successful use in the post-synaptic NMJ disorder muscle-specific kinase-
myasthenia gravis (MuSK-MG), amifampridine could potentially modulate both pre- and post-synaptic defects
observed in SMA NMJs (ClinicalTrials.Gov ID: NCT03304054) [78–80].
MuSK-MG is caused by an antibody-mediated breakdown of MuSK, a specialized RTK that regulates motor
endplate development, maturation and AChR clustering through an agrin-MuSK-LRP4 cascade [81–84]. Although
there are limited studies of MuSK regulation in SMA, agrin dysregulation contributes to impaired AChR clustering,
suggesting that the agrin-MuSK-LRP4 cascade may be a suitable target for SMA treatments [85,86]. Although
not yet in clinical trials, preliminary work is currently ongoing to evaluate the therapeutic potential of MuSK-
specific antibody agonists aimed at increasing MuSK activity (Figure 1) [87,88]. Increasing MuSK activity either
genetically or pharmacologically in SOD1G93A ALS mice resulted in reduced NMJ denervation and improved
motor function [89,90]. Although the MuSK antibody agonist did not influence survival rate or disease progression
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in ALS mice, its ability to maintain NMJ integrity and innervation makes it an interesting candidate that could
potentially be combined with amifampridine to reduce NMJ pathology in SMA (Figure 1).
From a repositioning approach, one limitation in the use of NMJ-specific drugs for SMA treatment is that
they were originally designed to treat disorders that display either pre- or post-synaptic NMJ defects. However,
both compartments are affected in SMA and studies in ALS mice indicate that these pharmacological compounds
may not be as effective when administered individually. Instead, future research endeavors in SMA could adopt a
combinatorial approach when trialing NMJ targeting drugs to ensure optimal benefits.
Repositioning drugs for skeletal muscle pathologies in SMA
Reduced SMN levels also affect skeletal muscle development and function [91–94]. A new avenue for SMA thera-
peutic development could therefore involve drugs currently used for muscular disorders. Indeed, shared treatment
paradigms have recently been identified for SMA and Duchenne muscular dystrophy (DMD), an inherited X-
linked recessive muscle disorder [95]. Currently, the most commonly used drug to treat DMD is prednisolone,
a synthetic glucocorticoid, which was originally prescribed to reduce fibrotic development in skeletal muscle via
its anti-inflammatory properties [96,97]. Research in DMD mdx mice has recently demonstrated that when dosed
intermittently, prednisolone also displayed ergogenic benefits in skeletal muscle by increasing its repair [98,99]. The
molecular mechanism behind the prednisolone-induced muscle repair is thought to be through restoration of
Klf15 expression, a transcription factor involved in muscle homeostasis via regulation of glucose, lipid and amino
acid metabolism (Figure 1) [99–102]. Subsequently, Klf15 levels were also observed to be low in skeletal muscle of
pre-symptomatic SMA mice [103]. Importantly, prednisolone treatment in SMA mice increased Klf15 expression
and led to amelioration of muscle-specific phenotypes, weight and survival [103]. Evidence of common pathological
targets and treatment strategies between SMA and DMD supports further investigations into the repositioning of
additional muscle-specific drugs not previously considered for SMA.
Tideglusib, a small heterocyclic thiadiazolidine-based non-ATP competitive inhibitor of GSK-3β, could po-
tentially ameliorate SMA muscle pathology (Figure 1) [104]. GSK-3β is a ubiquitously expressed isoform of
GSK-3, which acts as a serine/threonine kinase in many cellular processes such as proliferation, survival and
metabolism [105,106]. Tideglusib was initially developed for AD, with initial trials deeming the drug safe for human
use [107,108]. The ubiquitous and multipurpose activities of GSK-3β thus enabled repurposing opportunities for
tideglusib. In skeletal muscle, GSK-3β is a negative regulator of growth through dysregulation of the myogenic
regulator factors [109]. When GSK-3β was inhibited in C2C12 myoblasts and C57BL/6 mice, myogenic regulator
factor activity, myotube formation and muscle growth were enhanced, confirming its usefulness as a potential drug
candidate for impaired muscle development [109–111]. As such, tideglusib is being evaluated in Phase II clinical trials
(ClinicalTrials.gov ID: NCT03692312; NCT02858908) for congenital myotonic dystrophy, an autosomal polyQ-
dominant disorder characterized by myotonia, muscle dystrophy and weakness [112]. Although the trial results are
not fully published, early results are promising, suggesting that a Phase III approval is in the near future [113]. In
addition to promotion of muscle growth, tideglusib may have a further advantage in SMA by restoring SMN levels.
Indeed, chemical screens in human SMA fibroblasts exposed to GSK-3β inhibitors or GSK-3β short-hairpin RNAs
revealed an increased SMN expression [114]. With positive effects in congenital myotonic dystrophy and on SMN,
tideglusib could be a potential therapeutic candidate for SMA, ameliorating SMN-dependent and -independent
muscle atrophy.
The shared dysregulation in pathways related to muscle growth, differentiation, function and homeostasis
between muscular disorders and SMA highlights the contribution of intrinsic muscle defects to SMA pathogenesis.
The parallel continual development of pharmacological compounds for muscle disorders suggests that several
potential muscle-specific treatments could potentially lead to significant benefits for SMA.
Conclusion
Despite being the leading cause of genetically caused infant deaths, there is presently only one clinically approved
drug for SMA that is not accessible to all SMA patients and is unfortunately not a cure. Additional SMN-specific
drugs may be approved in the future, thus increasing treatment options (Table 1). However, molecular and func-
tional pathological similarities between SMA and other neurodegenerative, neuromuscular and muscular disorders
highlight potential novel non-SMN treatments (Figure 1). Indeed, the existence of shared dysregulated pathways
between diseases offers a therapeutic solution in the form of drug repositioning. Pharmacological compounds
that are either approved or in clinical trials could provide SMA patients more affordable and accessible treatment
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options that could be used in combination with SMN-dependent therapeutics. Furthermore, while the present
review focuses on the potential of repurposing drugs currently in use for neurodegenerative, neuromuscular and
muscular disease, repositioning strategies for SMA should not be limited to these groups of disorders as pathological
overlaps may also exist between SMA and unrelated disorders such as cancer (e.g., RTK signaling) [115]. With several
published multi-omics SMA studies identifying a multitude of dysregulated pathways and molecular effectors, the
opportunities for drug repositioning are many and should be a key component of future therapy development for
SMA (Figure 2) [116–118].
Future perspective
It is clear that the SMA therapeutic landscape has drastically changed since the approval of nusinersen/Spinraza™. In
the next few years, it is likely that most, if not all, SMA patients will have been administered one form or another of
an SMN-enhancing therapy (antisense oligonucleotide, gene therapy, small molecule). Our role as researchers and
clinicians is to support the SMA community by anticipating additional therapeutic needs as these presently young
children reach adolescence and adulthood. SMN-dependent therapies will without a doubt have to be accompanied
by complementary treatments aimed at ameliorating and/or preserving neuromuscular health in SMA patients.
Our goal should be to develop these drug entities well ahead of them being required, which can be ensured by
understanding the pathological similarities between SMA and other diseases and by using this information for drug
repositioning strategies.
Executive summary
Spinal muscular atrophy
• Spinal muscular atrophy (SMA) is an inherited neuromuscular disorder and the leading genetic cause of infant
mortality caused by homozygous loss of the SMN1 gene.
• Disease severity is dependent upon the copy number of SMN2, a duplicated but mutated copy of SMN1, which
only produces 10% of full-length protein.
• The benefits of the only currently available treatment for SMA (nusinersen/Spinraza™), an antisense
oligonucleotide that promotes expression of full-length SMN from SMN2, are limited by its accessibility and
age-dependent efficacy.
Drug repositioning
• There is currently a gap in treatment availability for SMA patients.
• Drug repositioning provides a shorter and more cost-effective transition to the clinic as pre-clinical and clinical
dosage and safety assessments have already been performed.
• Molecular and functional similarities between SMA and other neurodegenerative, neuromuscular and muscle
disorders present opportunities for drug repositioning strategies.
Rasalgiline
• Rasalgiline (Azilect™) is an irreversible MOA-B inhibitor that promotes neuroprotection in Parkinson’s Disease
through increased mitochondrial stability.
• Mitochondrial instability has been reported in pre-symptomatic SMA and amyotrophic lateral sclerosis (ALS)
motor neurons, which has led to rasalgiline Phase II clinical trials in the latter.
Masitinib
• Masitinib (Masivet™) is a CSF1 receptor inhibitor, which reduces microglia- and neuroinflammation-induced
neuronal loss.
• A Phase III clinical trial of masitinib in ALS patients revealed delayed neuronal degeneration, with similar results
in ALS mice that were associated with reduced microglial activity.
• Although masitinib has not been trialled in SMA, neuroinflammation-induced neuronal loss has been reported,
suggesting potential benefits of the drug in SMA.
Amifampridine
• Amifampridine (Firdpase™) is a pre-synaptic K+ channel blocker used in neuromuscular junction disorders such as
Lambert-Eaton myasthenic syndrome to promote ACh release, which is impaired due to defective voltage-gated
Ca2+ channels.
• Similar voltage-gated Ca2+ channel defects have been reported in SMA motor neurons, suggesting
amifampridine could be effective in SMA.
Muscle-specific kinase antibody agonist
• The agrin-MuSK-LRP4 cascade is important for ACh receptor remodeling at the post-synaptic motor endplate.
• ACh receptor remodeling is dysregulated in a variety of neuromuscular disorders such as SMA, ALS and
MuSK-myasthenia gravis.
• A MuSK antibody agonist, previously designed to promote MuSK activity in MuSK-myasthenia gravis, improved
motor function in ALS mice, suggesting it could have similar benefits in SMA.
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Prednisolone
• Prednisolone is a synthetic glucocorticoid used in Duchenne muscular dystrophy that demonstrates
anti-inflammatory and ergogenic properties.
• In both Duchenne muscular dystrophy and SMA mice, prednisolone improves muscle health through restoration
of Klf15 activity, an important regulator of muscle metabolism.
Tideglusib
• Tideglusib is a small heterocyclic thiadiazolidine-based non-ATP competitive inhibitor of GSK-3β.
• In skeletal muscle, GSK-3β negatively regulates myogenic regulatory factor activity and its inhibition is associated
with muscle growth.
• Tideglusib is currently showing promising results in Phase II clinical trials for the muscle disorder congenital
myotonic dystrophy.
• Tideglusib could potentially ameliorate SMA skeletal muscle through both SMN-dependent and -independent
pathways.
Second-generation SMA therapies
• There is increasing evidence that future treatments need to incorporate both SMN-dependent and -independent
therapies that affect both neuronal and systemic tissues.
• The increasing number of multi-omic studies will allow for the identification of drug target similarities between
SMA and different disorders.
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